“It is clear from the SURPASS-SWITCH study that delaying ... or less and weight loss of 10% or greater without hypoglycemia were 47.4% with tirzepatide vs 4.8% with dulaglutide.

For example, analysis of data from the SURPASS-3 trial by Viljoen et al. revealed that the median time to first achieve the HbA1c of 7.0% was 8.1 weeks for each dose of tirzepatide compared with ...

“The results of SURPASS-6 further support the role ... of participants in the fast-acting insulin group experienced hypoglycemia. Tirzepatide known by the brand-name Mounjaro, appears to be ...

"Results from SURPASS-SWITCH suggest that escalating dulaglutide is not as effective in reducing HbA1c and may further delay diabetes control than switching to tirzepatide," they wrote.

have been found across the series of Surpass trials that studied tirzepatide in people with type 2 diabetes, according to an analysis of studies published in March 2023 in the journal ...

The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. In this phase 3 ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

The present review explores the in vitro and in vivo benefits of Tirzepatide's effects, with notes on the drug's pleiotropic effects on other organs. It focuses on the SURPASS and SURMOUNT ...

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes. Published in The ...